Minimización de costes del mantenimiento con rituximab a intervalos fijos o individualizados en vasculitis por anticuerpos contra el citoplasma de los neutrófilos

Guisado-Gil, Ana Belén; Muñoz-Burgos, Marina; Ortega-Eslava, Ana; García-Hernández, Francisco Javier; Santos-Ramos, Bernardo.
Farm. hosp ; 44(2): 46-50, mar.-abr. 2020. tab
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-192387

Documentos relacionados

  1. Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis.
  2. Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophil-cytoplasm antibody associated vasculitides.
  3. Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
  4. Expert perspectives on pathological findings in vasculitis.
  5. Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.
  6. Association Between Plasma Rituximab Concentration and the Risk of Major Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides During Rituximab Maintenance Therapy.
  7. Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis.
  8. Antineutrophilic cytoplasmic antibody-associated vasculitis and the kidney.
  9. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic antibody-associated vasculitis.
  10. Old known and possible new biomarkers of ANCA-associated vasculitis.